Case Presenter

WesaGen, Inc.

WesaGen is a privately held biopharmaceutical company based in Worcester, Massachusetts. Its mission is to utilize its technology to discover and develop novel therapeutic drugs and devices to combat thrombocytopenia and cancer.

WesaGen is engaged in the near-term development of novel technologies to diagnose type 2 heparin-induced thrombocytopenia (HIT), a life-threatening condition; the development of a proprietary line of innovative and potent anti-angiogenic therapeutic drugs (thrombospondin- 1 type 1 repeats: TSP-1 TSRs) to treat cancer; and research and development based on a new innovative nanoscale drug delivery platform technology.

They project future growth through strategic alliances and collaboration with major pharmaceutical and biotechnology companies as well as with university medical departments that will use WesaGen's nanoscale drug delivery platform technology. This patented structural scaffold technology uses coiled-coil protein motifs as model systems for the self-assembly of rope-like biopharmaceutical(s) with well-defined structure and interaction features.

Led by Dr. Mustapha Abdelouahed, Ph.D., an expert in immunology, hemostasis, coagulation, cell and molecular biology of vessels, and Jack Lawler, Ph.D., Professor at Harvard Medical School, and considered to be one of the world's top authorities on the thrombospondin gene family, WesaGen is seeking private financing of $16 million in order to complete its product development agenda over the next five years.

Contact information:
Dr. Mustapha Abdelouahed, Ph.D, president
WesaGen, Inc.
339 Main Street
Worcester, MA 01608
Phone: 508-287-4346
Email: mabdelouahed2000@yahoo.com